A Phase 2, Parallel-Group, Double-Blind, 4-Arm Study to Investigate Weight Management With LY3305677 Compared With Placebo and in Adult Participants With Obesity or Overweight
Latest Information Update: 16 Apr 2025
At a glance
- Drugs Mazdutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
Most Recent Events
- 13 Jan 2025 Planned End Date changed from 16 May 2025 to 1 May 2025.
- 13 Jan 2025 Planned primary completion date changed from 29 Nov 2024 to 1 Jan 2025.
- 13 Jan 2025 Status changed from recruiting to active, no longer recruiting.